STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

1 . A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein:

W and Y are independently selected from S, O, NR 4 , or CR 4 ;

R 4 Is independently selected from hydrogen or an optionally substituted C 1 -C 4 aliphatic group;

R 1 represents hydrogen, halogen, hydroxy, amino, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, alkylthio, aryl, arylalkyl, heterocyclic, heteroaryl, heterocycloalkyl, alkylsulfonyl, alkoxycarbonyl and alkylcarbonyl.

R 2 Is selected from:

(i) amino, alkyl amino, aryl amino, heteroaryl amino; or

(ii) groups of the formula (Ia):

wherein:

R 5 represents hydrogen, C 1 -C 4 alkyl, oxo;

X is CH, when R 6 is hydrogen; or X—R 6 is O; or X is N, R 6 represents groups of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 aryl or heteroaryl, (C 3 -C 7 cycloalkyl)C 1 -C 4 alkyl, C r C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 2 -C 6 -alkanoyl, C 1 -C 6 alkoxycarbonyl, C 2 -C 6 alkanoyloxy, mono- and di-(C 3 -C 8 cycloalkyl)aminoC 0 -C 4 alkyl, (4- to 7-membered heterocycle)C 0 -C 4 alkyl, C 1 -C 6 alkylsulfonyl, mono- and di-(C 1 -C 6 alkyl)sulfonamido, and mono- and di(C 1 -C 6 alkyl)aminocarbonyl, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, amino, —COOH and oxo,

R3 is 0 to 5 substituents independently chosen from:

(i) halogen, hydroxy, amino, amide, cyano, —COOH, —SO 2 NH 2 , oxo, nitro and alkoxycarbonyl; and

(ii) C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkanoyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, mono- and di-(C 1 -C 6 alkyl)amino, C 1 -C 6 alkylsulfonyl, mono- and di-(C 1 -C 6 alkyl)sulfonamido and mono- and di-(C 1 -C 6 lkyl)aminocarbonyl, phenylC 0 -C 4 alkyl and (4- to 7-membered heterocycle)C 0 -C 4 alkyl, each of which is substituted with from 0 to 4 secondary substituents independently chosen from halogen, hydroxy, cyano, oxo, imino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy and C 1 -C 4 haloalkyl;

wherein the carbon double bonds may occur in Z- and E-forms.

2 . A process for making compound of claim 1 or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof.

3 . A pharmaceutical composition comprising at least one compound of claim 1 or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof, and a pharmaceutically acceptable carrier.

4 . A compound selected from the group consisting of:

5 . The composition according to claim 3 , further comprising an additional therapeutic agent.

6 . A method for treating a disease or condition in a mammal characterized by undesired cellular proliferation or hyperproliferation comprising identifying the mammal afflicted with said disease or condition and administering to said afflicted mammal a composition comprising the compound of claim 1 .

7 . The method of claim 6 , wherein the disease or condition is cancer, stroke, congestive heart failure, an ischemia or reperfusion injury, arthritis or other arthropathy, retinopathy or vitreoretinal disease, macular degeneration, autoimmune disease, vascular leakage syndrome, inflammatory disease, edema, transplant rejection, burn, or acute or adult respiratory distress syndrome.

8 . A compound as shown in Formula (A):

or a pharmaceutically acceptable salt thereof, wherein:

Y is selected from —NR 4 R 5 , and -Q-R 3 ;

Q is heterocycloalkyl, which is optionally substituted with C 1 -C 4 alkyl or oxo;

R 3 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkyl-R 6 , aryl, and heteroaryl;

R 4 and R 5 are each independently selected from H, and C 1 -C 6 alkyl;

R 6 is selected from hydroxy, —NH 2 , mono(C 1 -C 6 alkyl)amino, di(C 1 -C 6 alkyl)amino, cycloalkyl, and heterocycloalkyl;

X is —K—Ar 1 —R 1 ;

K is selected from —CH═CH— and —C≡C—;

Ar 1 is selected from phenyl and thiazolyl;

R 1 is selected from H, C 1 -C 6 alkyl, halo, (C 1 -C 6 )haloalkyl, —OR 4 , and —NH 2 ;

Z is —NH—Ar 2 —R 2 ,

Ar 2 is heteroaryl including at least one nitrogen;

R 2 is selected from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and phenyl.

9 . A compound as shown in Formula (A):

or a pharmaceutically acceptable salt thereof, wherein:

Y is selected from —NR 4 R 5 , and -Q-R 3 ;

Q is heterocycloalkyl, which is optionally substituted with C 1 -C 4 alkyl or oxo;

R 3 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkyl-R 6 , aryl, and heteroaryl;

R 4 and R 5 are each independently selected from H, and C 1 -C 6 alkyl;

R 6 is selected from hydroxy, —NH 2 , mono(C 1 -C 6 alkyl)amino, di(C 1 -C 6 alkyl)amino, cycloalkyl, and heterocycloalkyl;

X is —K—Ar 1 —R 1 ;

K is selected from —CH═CH— and —C≡C—;

Ar 1 is selected from phenyl and thiazolyl;

R 1 is selected from H, C 1 -C 6 alkyl, halo, (C 1 -C 6 )haloalkyl, —OR 4 , and —NH 2 ;

Z is —NH—Ar 2 —R 2 ;

Ar 2 is heteroaryl including at least one nitrogen; and

R 2 is selected from C 1 -C 6 alkyl and C 2 -C 6 alkenyl.

10 . A compound as shown in Formula (A):

or a pharmaceutically acceptable salt thereof, wherein:

Y is -Q-R 3 ;

Q is piperazinyl;

R 3 is C 1 -C 6 alkyl;

X is —K—Ar 1 —R 1 ;

K is selected from —CH═CH— and —C≡O—;

Ar 1 is selected from phenyl and thiazolyl;

R 1 is selected from H, C 1 -C 6 alkyl, and halo;

Z is —NH—Ar 2 —R 2 ,

Ar 2 is selected from pyrazolyl and thiazolyl; and

R 2 is selected from C 1 -C 6 alkyl, phenyl, and C 2 -C 6 alkenyl.

11 . A process for making compound of claim 8 or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof.

12 . A pharmaceutical composition comprising at least one compound of claim 8 or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof, and a pharmaceutically acceptable carrier.

13 . A method for treating a disease or condition in a mammal characterized by undesired cellular proliferation or hyperproliferation comprising identifying the mammal afflicted with said disease or condition and administering to said afflicted mammal a composition comprising the compound of claim 8 .

14 . A process for making compound of claim 9 or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof.

15 . A pharmaceutical composition comprising at least one compound of claim 9 or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof, and a pharmaceutically acceptable carrier.

16 . A method for treating a disease or condition in a mammal characterized by undesired cellular proliferation or hyperproliferation comprising identifying the mammal afflicted with said disease or condition and administering to said afflicted mammal a composition comprising the compound of claim 9 .

17 . A process for making compound of claim 10 or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof.

18 . A pharmaceutical composition comprising at least one compound of claim 10 or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms salts and individual diastereomers thereof, and a pharmaceutically acceptable carrier.

19 . A method for treating a disease or condition in a mammal characterized by undesired cellular proliferation or hyperproliferation comprising identifying the mammal afflicted with said disease or condition and administering to said afflicted mammal a composition comprising the compound of claim 10 .